Literature DB >> 27042838

Pharmacokinetics and immunological outcomes of alemtuzumab-based treatment for steroid-refractory acute GvHD.

S-K Tey1,2, S Vuckovic1, A Varelias1, J P Martins1, S Olver1, L Samson1, E Sturgeon2, J Leach2, J Avery2, M Nakagaki2, J P Butler2, C Curley2, A J Morton2, S T Durrant2, G A Kennedy1,2, G R Hill1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27042838     DOI： 10.1038/bmt.2016.83

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.

Authors:  Pooja Khandelwal; Julia Lawrence; Alexandra H Filipovich; Stella M Davies; Jacob J Bleesing; Michael B Jordan; Parinda Mehta; Sonata Jodele; Michael S Grimley; Ashish Kumar; Kasiani Myers; Rebecca A Marsh
Journal:  Pediatr Transplant       Date:  2013-10-30

2.  Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective.

Authors:  N Schub; A Günther; A Schrauder; A Claviez; C Ehlert; M Gramatzki; R Repp
Journal:  Bone Marrow Transplant       Date:  2010-03-29       Impact factor: 5.483

3.  Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications.

Authors:  Emma C Morris; Peppy Rebello; Kirsty J Thomson; Karl S Peggs; Charalampia Kyriakou; Anthony H Goldstone; Stephen Mackinnon; Geoff Hale
Journal:  Blood       Date:  2003-03-06       Impact factor: 22.113

4.  Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.

Authors:  H Glucksberg; R Storb; A Fefer; C D Buckner; P E Neiman; R A Clift; K G Lerner; E D Thomas
Journal:  Transplantation       Date:  1974-10       Impact factor: 4.939

5.  Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease.

Authors:  G A Kennedy; J Butler; R Western; J Morton; S Durrant; G R Hill
Journal:  Bone Marrow Transplant       Date:  2006-05-08       Impact factor: 5.483

Review 6.  First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.

Authors:  Paul J Martin; J Douglas Rizzo; John R Wingard; Karen Ballen; Peter T Curtin; Corey Cutler; Mark R Litzow; Yago Nieto; Bipin N Savani; Jeffrey R Schriber; Paul J Shaughnessy; Donna A Wall; Paul A Carpenter
Journal:  Biol Blood Marrow Transplant       Date:  2012-04-14       Impact factor: 5.742

7.  Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.

Authors:  David Gómez-Almaguer; Guillermo J Ruiz-Argüelles; Luz del Carmen Tarín-Arzaga; Oscar González-Llano; Homero Gutiérrez-Aguirre; Olga Cantú-Rodríguez; José Jaime-Pérez; Antonio Carrasco-Yalán; Sergio Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2008-01       Impact factor: 5.742

8.  Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.

Authors:  Xin Zhang; Yazhong Tao; Manisha Chopra; Mihye Ahn; Karen L Marcus; Neelima Choudhary; Hongtu Zhu; Silva Markovic-Plese
Journal:  J Immunol       Date:  2013-11-06       Impact factor: 5.422

9.  Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study.

Authors:  Carmen Martínez; Carlos Solano; Christelle Ferrá; Antonia Sampol; David Valcárcel; José Antonio Pérez-Simón
Journal:  Biol Blood Marrow Transplant       Date:  2009-03-09       Impact factor: 5.742

10.  Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response.

Authors:  D R Mould; A Baumann; J Kuhlmann; M J Keating; S Weitman; P Hillmen; L R Brettman; S Reif; P L Bonate
Journal:  Br J Clin Pharmacol       Date:  2007-05-16       Impact factor: 4.335
View more
  2 in total

Review 1.  The immunological function of CD52 and its targeting in organ transplantation.

Authors:  Yang Zhao; Huiting Su; Xiaofei Shen; Junfeng Du; Xiaodong Zhang; Yong Zhao
Journal:  Inflamm Res       Date:  2017-03-10       Impact factor: 4.575

2.  A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Pooja Khandelwal; Chie Emoto; Tsuyoshi Fukuda; Alexander A Vinks; Lisa Neumeier; Christopher E Dandoy; Javier El-Bietar; Sharat Chandra; Stella M Davies; Jacob J Bleesing; Michael B Jordan; Parinda A Mehta; Sonata Jodele; Michael S Grimley; Ashish Kumar; Kasiani C Myers; Rebecca A Marsh
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-21       Impact factor: 5.742
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.